Although some studies reported that patients with T2DM have lower circulating quantities of adiponectin than those without T2DM [38, 39], other studies have shown that, under various kidney disease conditions [40, 41] and in patients with T2DM with CKD [42, 43] the serum adiponectin levels are increased, which corroborates our findings. Here, ADIPOQ is linked to kidney disorder.